PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 10, 2025RSC Medicinal Chemistry0 citationsOpen Access

Naphthalimide-organometallic hybrids as multi-targeted anticancer and luminescent cellular imaging agents

View Full Paper
DMDavid C. MagriAJAlex D. Johnson

Key Points

  • Naphthalimide-organometallic hybrids exhibit significant anticancer properties, suggesting potential treatment options.
  • These hybrids also demonstrate effective luminescent properties, facilitating cellular imaging applications.
  • Intelligent agent design may enhance the specificity of treatment and sensing in targeted applications.
  • Further research is necessary to fully understand their mechanisms and optimize their effectiveness.

Abstract

Naphthalimide–organometallic hybrids are reviewed as intelligent agents for antineoplastic and luminescence sensing applications.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Magri et al. (2025) studied this question.

synapsesocial.com/papers/68c1c63e54b1d3bfb60f2454https://doi.org/10.1039/d5md00205b
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Chloroquine-induced DNA damage synergizes with DNA repair inhibitors causing cancer cell death2024 · 14 citations
  2. 2A New Class of Naphthalimide-Based Antitumor Agents That Inhibit Topoisomerase II and Induce Lysosomal Membrane Permeabilization and Apoptosis2010 · 169 citations
  3. 3Organometallic Antitumor Compounds: Ferrocifens as Precursors to Quinone Methides2015 · 79 citations
  4. 4Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?2018 · 476 citations
  5. 5Light enhanced cytotoxicity and antitumoral effect of a ruthenium-based photosensitizer inspired from natural alkaloids2024 · 3 citations